

10257.864

DT16 Rec'd T/PTO 04 APR 2003

Atty. Dkt. No. 065678/0108

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: **Naoshi Fukushima, et al.**

Title: **AGONIST ANTIBODIES**

Prior Appl. **PCT/JP01/03288**  
No.:

Prior Filing **April 17, 2001**  
Date:

Examiner: **Not Yet Assigned**

Art Unit: **Not Yet Assigned**

RECEIVED  
APR 29 2003  
OFFICE OF PETITIONS

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited during the prosecution of the corresponding International application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

**RELEVANCE OF EACH DOCUMENT**

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding International application. Copies of the documents are not being provided since copies should have been provided directly by WIPO under an exchange program between the PTO, the EPO and the JPO. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date 4/3/03

By Eve L. Frank

FOLEY & LARDNER  
Customer Number: 22428

Eve L. Frank  
Registration No. 46,785



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5569

Facsimile: (202) 672-5399

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: April 2, 2003 (use as many sheets as necessary)				<b>Complete if Known</b>		
				Application Number		Not Yet Assigned
				Filing Date		January 24, 2003
				First Named Inventor		Naoshi Fukushima, et al.
				Group Art Unit		Not Yet Assigned
				Examiner Name		Not Yet Assigned
Attorney Docket Number				065678-0108		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	4,946,778	A	GENEX CORP.	08/07/1990	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	A2	WO	00/53634	A1	CHUGAI SEIYAKU KABUSHIKI KAISHA	09/14/2000		
	A3	WO	99/12973	A1	CHUGAI SEIYAKU KABUSHIKI KAISHA	03/18/1999		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A4	MATEO ET AL., "CD 47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia," <i>Nature Medicine</i> (November 1999), vol. 5, No. 11, pp. 1277-1284.		
	A5	PETTERSEN, ET AL., "CD47 signals T cell death," <i>J. Immunol.</i> (15 June 1999), Vol. 162, No. 12, pp. 7031-7040.		
	A6	ROZSNYAY ET AL., "Phenylarsine oxide (PAO) blocks antigen receptor-induced calcium response and tyrosine phosphorylation of a distinct group of proteins," <i>Immunology Lett.</i> (August 1993), Vol. 37, Nos. 2 – 3, pp. 197-205.		
	A7	BAZZONI ET AL., "Chimeric tumor necrosis factor receptors with constitutive signaling activity," <i>Proc. Natl. Acad. Sci. USA</i> (6 June 1995), Vol. 92, No. 12, pp. 5376-5580.		
	A8	GELL ET AL., "TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis," <i>Lymphokine and Cytokine Research</i> (June 1993), Vol. 12, No. 3, pp. 143-148.		
	A9	O'BRIEN ET AL., "Monoclonal antibodies for the human insulin receptor stimulate intrinsic receptor-kinase activity," <i>Biochim. Soc. Trans.</i> (1986), Vol. 14, No. 6, pp. 1021-1023.		
	A10	YARDEN ET AL., "Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation," <i>Biochemistry</i> (1987), Vol. 26, No. 5, pp. 1434-1442.		
	A11	YANABU ET AL., "Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein Ib monoclonal antibody," <i>Blood</i> (1997), Vol. 89, No. 5, pp. 1590-1598.		

RECEIVED  
APR 29 2003

Examiner Signature	Date Considered	OFFICE OF PETITIONS
--------------------	-----------------	---------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.